drugset
drugset / Trial / NCT00925574

A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With Psoriasis

NCT00925574 ↗

Phase 1 Completed 71 enrolled Centocor, Inc.
RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety and how the body affects a drug (CNTO 1959) in healthy volunteers and in patients with psoriasis.

Timeline

Start
2009-06-04
Primary completion
2010-10-11
Completion
2010-10-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Guselkumab Monoclonal antibody — Intravenous

Indications

psoriasis